We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

66 hedge funds and large institutions have $6.6M invested in Protalix BioTherapeutics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 12 increasing their positions, 16 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,400% more call options, than puts

Call options by funds: $125K | Put options by funds: $5K

17% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 23

5% more funds holding

Funds holding: 63 → 66 (+3)

5.16% less ownership

Funds ownership: 12.85% → 7.69% (-5.2%)

25% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 16

45% less capital invested

Capital invested by funds: $11.9M → $6.6M (-$5.32M)

Holders
66
Holders Change
+3
Holders Change %
+4.76%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
12
Reduced
16
Closed
23
Calls
$125K
Puts
$5K
Net Calls
+$120K
Net Calls Change
+$75K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$946K
2
Goldman Sachs
Goldman Sachs
New York
+$437K
3
Jane Street
Jane Street
New York
+$309K
4
YIH
Y-Intercept (HK)
Hong Kong
+$187K
5
CC
Centiva Capital
New York
+$154K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.52M
2
State Street
State Street
Massachusetts
-$1.04M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$950K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$416K
5
N
Nuveen
North Carolina
-$342K
Name Holding Trade Value Shares
Change 		Change in
Stake
Verition Fund Management
76
Verition Fund Management
Connecticut
– -$29.6K -23,465 Closed
AllianceBernstein
77
AllianceBernstein
Tennessee
– -$29.5K -23,400 Closed
Wells Fargo
78
Wells Fargo
California
– -$29.4K -23,369 Closed
SG Americas Securities
79
SG Americas Securities
New York
– -$27K -21,467 Closed
T. Rowe Price Associates
80
T. Rowe Price Associates
Maryland
– -$21K -15,982 Closed
ProShare Advisors
81
ProShare Advisors
Maryland
– -$15.3K -12,147 Closed
California State Teachers Retirement System (CalSTRS)
82
California State Teachers Retirement System (CalSTRS)
California
– -$8.56K -6,797 Closed
Legal & General Group
83
Legal & General Group
United Kingdom
– -$6.75K -5,359 Closed
AIP
84
Ameritas Investment Partners
Nebraska
– -$5.84K -4,638 Closed
TC
85
Truvestments Capital
Florida
– -$4.89K -3,880 Closed
AB
86
Amalgamated Bank
New York
– -$2K -1,894 Closed
Simplex Trading
87
Simplex Trading
Illinois
– -$463 -392 -85%
N
88
Natixis
France
– -$126 -100 Closed
AWM
89
Avior Wealth Management
Nebraska
– -$11 -9 Closed
1 2 3
4

PLX Hedge Fund Activity: Q2 2024 in Review

66 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2024, worth a combined $6.6M — down 45% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new PLX positions and 23 closed out — a net gain of 4 holders — while 12 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, adding an estimated $946K. The largest seller was BlackRock, cutting an estimated $3.52M.

  • 66 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2024, up from 63 in Q1 2024.
  • Funds reported $6.6M of Protalix BioTherapeutics stock for Q2 2024, down 45% quarter-over-quarter.
  • 27 funds opened new Protalix BioTherapeutics positions in Q2 2024 and 23 closed out, a net change of +4 holders.
  • The largest Protalix BioTherapeutics buyer in Q2 2024 was Millennium Management, an estimated $946K added.
  • The largest Protalix BioTherapeutics seller in Q2 2024 was BlackRock, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2024.